Bimagrumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bimagrumab
Accession Number
DB12584
Description

Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
  • BYM338

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Bimagrumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Bimagrumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimagrumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Bimagrumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Bimagrumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Bimagrumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimagrumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Bimagrumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Bimagrumab.
AvelumabThe risk or severity of adverse effects can be increased when Avelumab is combined with Bimagrumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
N15SW1DIV8
CAS number
1356922-05-8

References

General References
Not Available
PubChem Substance
347911347
Wikipedia
Bimagrumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentSporadic Inclusion Body Myositis1
2CompletedSupportive CareChronic Obstructive Pulmonary Disease (COPD) With Cachexia1
2CompletedTreatmentCachexia1
2CompletedTreatmentMuscle Wasting (Atrophy) After Hip Fracture Surgery1
2CompletedTreatmentSarcopenia2
2CompletedTreatmentSkeletal Muscle1
2CompletedTreatmentSporadic Inclusion Body Myositis1
2CompletedTreatmentType 2 Diabetes Mellitus1
2WithdrawnNot AvailableVentilations, Mechanical1
2, 3CompletedTreatmentSporadic Inclusion Body Myositis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 17:02 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates